In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Jumping on the Vertebroplasty Bandwagon

Executive Summary

With estimates for the number of current procedures now at 35,000-40,000 and growing, established spinal orthopedics companies are beginning to cash in on the rapidly growing use of bone cements and cement delivery systems for vertebral compression fracture repair, or vertebroplasty. To date, Cook Group and Medtronic Sofamor Danek have been supplying the majority of kits. Danek also recently began selling a PMMA resin tailored for vertebroplasty, and Stryker has indicated that it too has its sights set on the vertebroplasty opportunity: it is currently reformulating one of its existing cement products for use in vertebroplasty. That Stryker and Danek-- both industry leaders in orthopedics - are positioning themselves in this market suggests that it may be the next hot area in spine.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

IV001747

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel